CA2871385A1 - Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer - Google Patents

Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer Download PDF

Info

Publication number
CA2871385A1
CA2871385A1 CA2871385A CA2871385A CA2871385A1 CA 2871385 A1 CA2871385 A1 CA 2871385A1 CA 2871385 A CA2871385 A CA 2871385A CA 2871385 A CA2871385 A CA 2871385A CA 2871385 A1 CA2871385 A1 CA 2871385A1
Authority
CA
Canada
Prior art keywords
patient
biomarker
expression level
vegf antibody
cancer therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2871385A
Other languages
English (en)
French (fr)
Inventor
Ursula Klause
Nicola MOORE
Celine Pallaud
Stefan Scherer
Norbert Wild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2871385A1 publication Critical patent/CA2871385A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2871385A 2012-06-26 2013-06-24 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer Abandoned CA2871385A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664612P 2012-06-26 2012-06-26
US61/664,612 2012-06-26
US201261697667P 2012-09-06 2012-09-06
US61/697,667 2012-09-06
PCT/EP2013/063094 WO2014001232A1 (en) 2012-06-26 2013-06-24 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Publications (1)

Publication Number Publication Date
CA2871385A1 true CA2871385A1 (en) 2014-01-03

Family

ID=48672633

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2871385A Abandoned CA2871385A1 (en) 2012-06-26 2013-06-24 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Country Status (10)

Country Link
EP (1) EP2864788A1 (ja)
JP (1) JP2015522815A (ja)
KR (1) KR20150024342A (ja)
CN (1) CN104364655A (ja)
BR (1) BR112014032456A2 (ja)
CA (1) CA2871385A1 (ja)
HK (1) HK1202334A1 (ja)
MX (1) MX2014014821A (ja)
RU (1) RU2015102026A (ja)
WO (1) WO2014001232A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018164518A1 (ko) * 2017-03-08 2018-09-13 한양대학교 산학협력단 Her2 양성 암 및 항-her2 치료에 대한 바이오마커 및 이의 용도
KR102028703B1 (ko) * 2017-11-21 2019-10-04 한양대학교 산학협력단 유방암의 진단 및 치료를 위한 바이오 마커

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE97498T1 (de) 1984-01-30 1993-12-15 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5081034A (en) 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE19806989A1 (de) 1998-02-19 1999-08-26 Roche Diagnostics Gmbh Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004029909A1 (de) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern
US20090123930A1 (en) * 2007-11-09 2009-05-14 Wu Thomas D Methods and compositions for diagnostic use in cancer patients
JP4719930B2 (ja) * 2008-02-29 2011-07-06 国立大学法人信州大学 センチネルリンパ節内転移癌細胞検出用薬物輸送剤
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
MX2012000620A (es) * 2009-07-13 2012-01-27 Genentech Inc Metodos diagnostico y composiciones para tratamiento de cancer.
KR20120059553A (ko) * 2009-08-14 2012-06-08 제넨테크, 인크. Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커
RU2558931C2 (ru) * 2010-01-12 2015-08-10 Нестек С.А. Способы предсказания ответа трижды негативного рака молочной железы на терапию
JP2013537522A (ja) * 2010-07-19 2013-10-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法

Also Published As

Publication number Publication date
CN104364655A (zh) 2015-02-18
BR112014032456A2 (pt) 2017-06-27
WO2014001232A1 (en) 2014-01-03
JP2015522815A (ja) 2015-08-06
HK1202334A1 (en) 2015-09-25
KR20150024342A (ko) 2015-03-06
MX2014014821A (es) 2015-02-12
EP2864788A1 (en) 2015-04-29
RU2015102026A (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
US20140341893A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2596363B1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
AU2011281700B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
JP2016026290A (ja) 抗癌治療への応答可能性の増大した患者を同定する方法
CA2804246A1 (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
US20150352204A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
CA2871385A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
NZ624444B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20180627